24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
Corporate
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Generics
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
Corporate
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
21:53
Google, Amazon and Intel stumble as investors begin to question the price of the AI boom
12:53
Every student deserves a personal tutor, inside the classroom, too.
09:51
AI companies say their models are the best. Here's how to tell if that's true
08:35
What if the AI runs out of electricity?
More stories
Buzz
Most popular
Daily
Weekly
1
"A gorgeous situation": ServiceNow's CEO celebrates a shrinking workforce
2
Intel shares plunge as Israel factory blast compounds weak outlook
3
Cyber startup Cyera eyes $20 billion valuation in new funding talks
4
Stealth Israeli cyber startup valued at over $1.5 billion recruits former 8200 chief
5
Nikesh Arora's pay falls 19.5% to $80 million as Palo Alto Networks board lowers cap on stock awards
More news
Generics
6 stories about Generics
Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself
11.11.19
|
Uri Tal-Tene
With one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year
Mylan Cuts Price of Generic Copaxone Offering by 60%
11.07.18
|
Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
Teva to Relocate U.S. Headquarters to New Jersey
08.07.18
|
Lilach Baumer
In December, the Israeli drugmaker announced a far-reaching cost cutting plan to deal with its multi-billion debt
Goldman Sachs Sees 16% Upside in Teva Stock
26.06.18
|
Dror Reich
Following a meeting with Teva’s management, the bank's analysts reiterated their "buy" recommendation with a higher target price
In Protest of New Bonus Plan, Teva Sued by Israeli Employees
15.03.18
|
Dror Reich
After announcing the cancellation of its annual bonuses for 2017 due to debt, the Israel-based drugmaker rolled out a performance-based bonus scheme for 2018 in February
Drugmaker Hikma Appoints Former Teva Executive as CEO
20.02.18
|
Asaf Shalev
The appointment of Sigurdur Olafsson comes as Hikma has been struggling to bolster the performance of its generic drugs unit
